Anbogen Therapeutics
安邦生技股份有限公司
Anbogen Therapeutics is a Taiwan Emerging Stock Board biotechnology company; its most advanced asset is ABT-301 (Phase 1 / Phase 2; recruiting, Colorectal Cancer (Diagnosis); Colorectal Cancer Metastatic; Colorectal Cancer (CRC); Immunotherapy), as of 2026-11-01.
Pipeline
| Asset | Target / mechanism | Stage | Indication | Region | Source date | Source |
|---|---|---|---|---|---|---|
| ABT-301 | HDAC inhibitor | Phase 1 / Phase 2; recruiting | Colorectal Cancer (Diagnosis); Colorectal Cancer Metastatic; Colorectal Cancer (CRC); Immunotherapy | Australia, Taiwan | 2025-11-24 | Trial registry |
| ABT-101 | — | Phase 1b completed; Phase 2 deferred | Advanced solid tumors; HER2 exon 20 insertion NSCLC | Taiwan | 2026-03-25 | Company disclosure |
| DBPR376 | — | Preclinical | LHRH-R-expressing tumors | — | 2025-01-17 | Company disclosure |
Key events
- ABT-101 Phase 1b final clinical study report received (company disclosure)